TELA Bio Reports Q1 2026 Earnings with Positive Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy TELA?
Source: seekingalpha
- Strategic Reset Showing Results: TELA Bio reported Q1 2026 revenue of $19.1 million, reflecting a 3% year-over-year increase, indicating early success of its commercial strategy reset, with CEO Koblish highlighting the effectiveness of the team and achievement of hiring targets to drive future performance.
- OviTex LTR Full Launch: The company initiated the full U.S. commercial launch of the OviTex long-term resorbable reinforcement portfolio on April 1, pricing it comparably to existing products to enhance value perception among surgeons and hospital administrators, which is expected to further boost sales growth.
- Strong European Market Performance: TELA Bio experienced a 41% revenue growth in Europe, validating its value proposition and securing OviTex's application in complex abdominal wall surgeries through NHS Supply Chain evaluation, showcasing the potential of international markets.
- Optimistic Future Outlook: The company reiterated its guidance for at least 8% revenue growth in 2026, with Q2 revenue projected at approximately $20.0 million, and management expressed confidence in significant performance improvements in the second half of the year, anticipating a productivity inflection point for the sales team.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TELA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TELA
Wall Street analysts forecast TELA stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.020
Low
1.25
Averages
3.31
High
5.00
Current: 1.020
Low
1.25
Averages
3.31
High
5.00
About TELA
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TELA Bio Reports Q1 2026 Earnings with Positive Outlook
- Strategic Reset Showing Results: TELA Bio reported Q1 2026 revenue of $19.1 million, reflecting a 3% year-over-year increase, indicating early success of its commercial strategy reset, with CEO Koblish highlighting the effectiveness of the team and achievement of hiring targets to drive future performance.
- OviTex LTR Full Launch: The company initiated the full U.S. commercial launch of the OviTex long-term resorbable reinforcement portfolio on April 1, pricing it comparably to existing products to enhance value perception among surgeons and hospital administrators, which is expected to further boost sales growth.
- Strong European Market Performance: TELA Bio experienced a 41% revenue growth in Europe, validating its value proposition and securing OviTex's application in complex abdominal wall surgeries through NHS Supply Chain evaluation, showcasing the potential of international markets.
- Optimistic Future Outlook: The company reiterated its guidance for at least 8% revenue growth in 2026, with Q2 revenue projected at approximately $20.0 million, and management expressed confidence in significant performance improvements in the second half of the year, anticipating a productivity inflection point for the sales team.
See More
TELA Bio Reports Q4 2025 Earnings with Strategic Changes
- Revenue Growth: TELA Bio reported an 18% year-over-year revenue increase in Q4 2025, reaching $20.9 million, with a full-year growth of 16% to $80.3 million, demonstrating resilience despite uncertainties from the sales team restructuring.
- Sales Team Rebuilding: The company has hired 40% of its sales representatives in the last six months, with CEO Koblish emphasizing this as an investment in commercial expansion, which is expected to drive future sales growth, although short-term challenges may arise during the onboarding of new reps.
- Product Innovation and Market Expansion: TELA Bio plans to launch more new products in 2026 to enhance market share, particularly in the U.S. market, with strong adoption of OviTex products in the U.K. and Netherlands indicating stability in international markets.
- Cautious Future Outlook: Management has set the revenue growth expectation for 2026 at a cautious 8%, reflecting a prudent approach to market changes, and despite challenges related to territory realignment and contract execution complexities, management remains optimistic about long-term growth.
See More
TELA Bio (TELA) Q4 2025 Earnings Call Transcript
See More
TELA Biopress Q4 Financial Results Analysis
- Financial Highlights: TELA Biopress reported a Q4 GAAP EPS of -$0.17, beating expectations by $0.01, although revenue of $20.9M, up 18.8% year-over-year, missed by $0.14M, indicating challenges in revenue growth despite positive trends.
- Gross Margin Improvement: The gross profit for Q4 was $13.8M, representing 65.9% of revenue, compared to $11.2M and 63.6% in the same period last year, with the margin increase primarily due to lower expenses related to excess and obsolete inventory adjustments, reflecting effective cost management.
- Reduced Operating Loss: The operating loss for Q4 2025 was $6.6M, an improvement from $8.4M in Q4 2024, indicating progress in controlling operational costs despite an overall increase in expenses, showcasing the company's efforts in financial discipline.
- 2026 Financial Guidance: The company anticipates at least 8% revenue growth in 2026, with first-quarter revenue projected at approximately $18.5M, demonstrating confidence in future growth driven by new customer acquisitions and international sales expansion.
See More
TELA BIO INC - Q4 REVENUE REACHED $20.9 MILLION
- Company Overview: Tela Bio Inc. reported a revenue of $20.9 million in the fourth quarter.
- Financial Performance: The revenue figure indicates a significant financial performance for the company during this period.
See More
TELA BIO PROJECTS REVENUE OF APPROXIMATELY $18.5 MILLION FOR Q1 2026
- Revenue Expectations: Tela Bio anticipates a revenue of approximately $18.5 million for the first quarter of 2026.
See More
TELA Bio Reports Q1 2026 Earnings with Positive Outlook
- Strategic Reset Showing Results: TELA Bio reported Q1 2026 revenue of $19.1 million, reflecting a 3% year-over-year increase, indicating early success of its commercial strategy reset, with CEO Koblish highlighting the effectiveness of the team and achievement of hiring targets to drive future performance.
- OviTex LTR Full Launch: The company initiated the full U.S. commercial launch of the OviTex long-term resorbable reinforcement portfolio on April 1, pricing it comparably to existing products to enhance value perception among surgeons and hospital administrators, which is expected to further boost sales growth.
- Strong European Market Performance: TELA Bio experienced a 41% revenue growth in Europe, validating its value proposition and securing OviTex's application in complex abdominal wall surgeries through NHS Supply Chain evaluation, showcasing the potential of international markets.
- Optimistic Future Outlook: The company reiterated its guidance for at least 8% revenue growth in 2026, with Q2 revenue projected at approximately $20.0 million, and management expressed confidence in significant performance improvements in the second half of the year, anticipating a productivity inflection point for the sales team.
See More
TELA Bio Reports Q4 2025 Earnings with Strategic Changes
- Revenue Growth: TELA Bio reported an 18% year-over-year revenue increase in Q4 2025, reaching $20.9 million, with a full-year growth of 16% to $80.3 million, demonstrating resilience despite uncertainties from the sales team restructuring.
- Sales Team Rebuilding: The company has hired 40% of its sales representatives in the last six months, with CEO Koblish emphasizing this as an investment in commercial expansion, which is expected to drive future sales growth, although short-term challenges may arise during the onboarding of new reps.
- Product Innovation and Market Expansion: TELA Bio plans to launch more new products in 2026 to enhance market share, particularly in the U.S. market, with strong adoption of OviTex products in the U.K. and Netherlands indicating stability in international markets.
- Cautious Future Outlook: Management has set the revenue growth expectation for 2026 at a cautious 8%, reflecting a prudent approach to market changes, and despite challenges related to territory realignment and contract execution complexities, management remains optimistic about long-term growth.
See More
TELA Bio (TELA) Q4 2025 Earnings Call Transcript
See More
TELA Biopress Q4 Financial Results Analysis
- Financial Highlights: TELA Biopress reported a Q4 GAAP EPS of -$0.17, beating expectations by $0.01, although revenue of $20.9M, up 18.8% year-over-year, missed by $0.14M, indicating challenges in revenue growth despite positive trends.
- Gross Margin Improvement: The gross profit for Q4 was $13.8M, representing 65.9% of revenue, compared to $11.2M and 63.6% in the same period last year, with the margin increase primarily due to lower expenses related to excess and obsolete inventory adjustments, reflecting effective cost management.
- Reduced Operating Loss: The operating loss for Q4 2025 was $6.6M, an improvement from $8.4M in Q4 2024, indicating progress in controlling operational costs despite an overall increase in expenses, showcasing the company's efforts in financial discipline.
- 2026 Financial Guidance: The company anticipates at least 8% revenue growth in 2026, with first-quarter revenue projected at approximately $18.5M, demonstrating confidence in future growth driven by new customer acquisitions and international sales expansion.
See More
TELA BIO INC - Q4 REVENUE REACHED $20.9 MILLION
- Company Overview: Tela Bio Inc. reported a revenue of $20.9 million in the fourth quarter.
- Financial Performance: The revenue figure indicates a significant financial performance for the company during this period.
See More
TELA BIO PROJECTS REVENUE OF APPROXIMATELY $18.5 MILLION FOR Q1 2026
- Revenue Expectations: Tela Bio anticipates a revenue of approximately $18.5 million for the first quarter of 2026.
See More
